Arcturus Therapeutics (ARCT) Expected to Announce Earnings on Monday

Arcturus Therapeutics (NASDAQ:ARCT) is projected to post its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Arcturus Therapeutics to post earnings of ($1.11) per share and revenue of $17.64 million for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analysts’ expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. On average, analysts expect Arcturus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcturus Therapeutics Price Performance

ARCT opened at $12.30 on Monday. The firm has a market cap of $333.58 million, a price-to-earnings ratio of -4.86 and a beta of 2.26. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $25.88. The company’s 50-day moving average price is $13.17 and its 200 day moving average price is $13.45. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.06.

Analyst Ratings Changes

Several research firms recently weighed in on ARCT. Citigroup reiterated a “buy” rating on shares of Arcturus Therapeutics in a research note on Tuesday, May 13th. Canaccord Genuity Group cut their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Wells Fargo & Company cut their price target on Arcturus Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Scotiabank reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Wednesday, July 2nd. Finally, Wall Street Zen cut Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and an average price target of $54.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARCT. AQR Capital Management LLC acquired a new position in shares of Arcturus Therapeutics during the first quarter valued at approximately $128,000. Millennium Management LLC bought a new stake in Arcturus Therapeutics during the first quarter worth approximately $4,892,000. Goldman Sachs Group Inc. boosted its holdings in Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after buying an additional 42,636 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Arcturus Therapeutics during the first quarter worth approximately $701,000. Finally, Strs Ohio bought a new stake in Arcturus Therapeutics during the first quarter worth approximately $89,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.